TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05831735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The 6-month APA program is supervised via the videoconference platform and/or carried out independently based on a personalized written program that is updated weekly. The program is based on structured sessions alternating 3 types of PA: aerobic sessions, stretching sessions and muscle strengthening sessions (to be practiced following the teacher's oral or written instructions).~The sessions last from 20 minutes to 1 hour and are of low to moderate intensity depending on the initial level of fitness. The sessions are structured, adapted and progressive. During the sessions, the exercises are adapted according to the means and materials available to the patients at home or in their immediate environment.~The patients will be progressively led to practice in an autonomous way (i.e., without supervision) but following an adapted, personalized and structured program. These PA sessions can be declared afterwards to the PA teacher,(duration and the exercises actually performed).
Study: NCT06459531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) Therapy
Description: Patients in this group will receive therapy using VR technology. This involves engaging in various sensorimotor training exercises and tasks in an immersive virtual environment. The VR sessions are designed to be interactive and adaptive, providing real-time feedback to the user. The exercises will target the improvement of motor functions, coordination, and strength of the affected upper extremity.~Duration and Frequency: The specific regimen may involve sessions several times a week, with each session lasting between 30 to 60 minutes, over a period of several weeks or months, depending on the study design.

Intervention type: OTHER
Group type: OTHER
Intervention: Conservative Treatment
Description: Patients in this group will receive traditional rehabilitation therapies, which may include:~Physical Therapy (PT): Exercises and activities aimed at improving strength, flexibility, and coordination of the upper limb.~Occupational Therapy (OT): Functional task training to enhance daily living skills and independence, focusing on the use of the upper extremity.~Manual Therapy: Techniques such as massage or joint manipulation to improve mobility and reduce pain.~Home Exercise Programs: Prescribed exercises to be performed at home to reinforce therapy sessions.~Duration and Frequency: Similar to the VR group, this regimen may involve regular sessions several times a week, with each session lasting between 30 to 60 minutes, over a comparable period.
Study: NCT05819359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 28-6156 10 mg
Description: BIA 28-6156 10 mg, once daily, oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 28-6156 60 mg
Description: BIA 28-6156 60 mg, once daily, oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily, oral administration.
Study: NCT05946044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Exercise
Description: Group and individual weight loss and weight maintenance sessions combined with exercise throughout the 48 months.
Study: NCT05016271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Air purifier and fresh air ventilation systems with high-efficiency particulate air (HEPA) filters
Description: This group will receive an intervention of true air purifiers. The air purifiers in classroom (air purifiers and fresh air ventilation systems with HEPA filters) will operate during the school time and the air purifiers in bedrooms (air purifiers with HEPA filters) operate during the home time in the intervention period (4 months anticipated).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Air purifier and fresh air ventilation systems without high-efficiency particulate air (HEPA) filters
Description: This group will receive an intervention of sham air purifiers. The air purifiers in classroom (air purifiers and fresh air ventilation systems without HEPA filters) will operate during the school time and the air purifiers in bedrooms (air purifiers without HEPA filters) operate during the home time in the intervention period (4 months anticipated).
Study: NCT06556979

Intervention type: RADIATION
Intervention: Radiotherapy
Description: Review imaging and medical record of head and neck cancer patient who recieve radiotherpy to find out the incidence of ischemic cerebrovascular event and carotid artery stenosis. The risk factor that influence new carotid artery stenosis was claculated
Study: NCT04800419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: ACT is a third generation cognitive behavioral approach which uses acceptance and mindfulness processes, and commitment and behavior change processes to produce psychological flexibility. ACT increase adaptive coping through acceptance, cognitive defusion, mindfulness, and perspective-taking exercises while supporting cancer survivors in aligning behavior with their personal values. The objectives of the therapy are for client to learn to focus on behaviors and actions that are in line with their individual values - the things they care about most. ACT facilitates development and maintenance of health behavioral improvements by targeting internal barriers, such as emotional discomfort and self-defeating thoughts, and by fostering connection and commitment to personal values associated with self-management of positive health behaviors. ACT is useful in cancer patients, because it can help them to deal with the negative emotions caused by cancer instead of avoiding these.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction (MBSR)
Description: The term 'mindfulness' refers to mindful awareness as a way of being - a knowing and experiencing of feelings, thoughts, and perceptions as they arise and pass away each moment. It is a way of relating to all experiences in an open, receptive way, without judging experiences as good or bad (grasping at them or pushing them away). Mindfulness employed two styles of meditations: concentrative meditation involves intentionally focusing attention on a chosen object (e.g. the sensations of breathing) in a sustained way, while receptive meditation involves monitoring the content of experience (e.g. sensations, emotions, thoughts, sounds, etc.) in a non-reactive and non-judgmental way, from moment to moment, with the goal being to recognize the nature of emotional and cognitive patterns. Mindfulness-based stress reduction (MBSR) is an 8-week, standardized group intervention consisting of mindfulness meditation and gentle yoga that is designed to have applications for stress, pain, and illness
Study: NCT06066125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK111
Description: AK111 regimen 1- subcutaneous injection at week 0,1,2, 3,4 and every 4 weeks thereafter until week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK111
Description: AK111 regimen 2- subcutaneous injection at week 0,1,2, 3,4 and every 4 weeks thereafter until week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.
Study: NCT05931731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical interference
Description: The patients will receive mechanical interference treatment in the form of five techniques, including wrist distraction (3 sets for 3 minutes), rhythmic and gentle stretching of the transverse carpal ligaments, the release of palmar hand fascia, gliding of the finger flexor tendons (using the oscillatory flexion-extension movement of the metacarpophalangeal joint) and release of the upper forearm muscle and fascia were applied. Manual techniques were performed total of 15 minutes in each session each technique included 3 sets for 3 minutes and conventional treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mobilization
Description: the patients will receive neurodynamic mobilizations, including sliding techniques and tensioning techniques which are thought to enhance ulnar nerve gliding and restore neural tissue mobility and conventional treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: the patients will receive therapeutic ultrasound (frequency of 1 MHz, intensity of 1 W/cm2, for 5 minutes), transcutaneous electrical nerve stimulation (TENS) (frequency of 80 Hz, pulse duration of 60 μs, at the level of comfortable tingling sensation, for 20 minutes) and therapeutic exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: the patients will receive therapeutic ultrasound (frequency of 1 MHz, intensity of 1 W/cm2, for 5 minutes), transcutaneous electrical nerve stimulation (TENS) (frequency of 80 Hz, pulse duration of 60 μs, at the level of comfortable tingling sensation, for 20 minutes) and therapeutic exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: the patients will receive therapeutic ultrasound (frequency of 1 MHz, intensity of 1 W/cm2, for 5 minutes), transcutaneous electrical nerve stimulation (TENS) (frequency of 80 Hz, pulse duration of 60 μs, at the level of comfortable tingling sensation, for 20 minutes) and therapeutic exercises.
Study: NCT06066125

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo- subcutaneous injection at week 0,1,2, 3, 4 and week 8. AK111 regimen 2-subcutaneous injection every 4 weeks from week 12 to week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.
Study: NCT05819957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Education Program (TEP)
Description: the TEP lasts 12 months, being structured into 6 modules.
Study: NCT05769114

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical stabilization
Description: Anterior-posterior stabilization (360°) with pedicle screws and an expandable cage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical stabilization
Description: Anterior-posterior stabilization (360°) with pedicle screws and an expandable cage
Study: NCT06301373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate Combined With Tofacitinib
Description: Methotrexate Combined With Tofacitinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate
Study: NCT05635006

Intervention type: OTHER
Description: No special intervention, randomly classify the subjects

Intervention type: OTHER
Description: No special intervention, randomly classify the subjects

Intervention type: OTHER
Description: No special intervention, randomly classify the subjects
Study: NCT05884125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Checkpoint BEST System
Description: Single use medical device, consisting of electric stimulator and intraoperative lead. Therapy consists of single, 10 minute dose delivered proximal to site of decompression/repair
Study: NCT04898777

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary drainage
Description: Biliary decompression in cases of distal malignant obstruction by stent placement either using ERCP or EUS.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary drainage
Description: Biliary decompression in cases of distal malignant obstruction by stent placement either using ERCP or EUS.
Study: NCT06160986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Horizons Group Intervention
Description: The Horizons Group intervention in English or Spanish language (per participant preference) contains 8 weekly group sessions delivered via video conference by a bone marrow transplant clinician and behavioral health specialist, over approximately 8 weeks, approximately 1.5 hours per session every week. The intervention pairs state-of-the-science information about survivorship and chronic graft versus host disease with self-management strategies. Intervention sessions will be delivered via video conference (Zoom), which participants may access by computer, laptop, tablet, or smart phone. As part of the intervention, participants will have access to an intervention manual and audio-recorded relaxation exercises to support learning and skills practice.
Study: NCT05089630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentamer (low)/gB(low)/Adjuvant vaccine
Description: Three doses of the candidate CMVsu vaccine consisting of a combination of low dose pentamer and low dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentamer (med)/gB(low)/Adjuvant vaccine
Description: Three doses of the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and low dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentamer (med)/gB(med)/Adjuvant vaccine
Description: Three doses of the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and medium dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentamer (high)/gB(med)/Adjuvant vaccine
Description: Three doses of the candidate CMVsu vaccine consisting of a combination of high dose pentamer and medium dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: Three doses of placebo (saline) are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
Study: NCT06523621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 2 cycles of nivolumab at a dose of 480 mg given over approximately 30-minutes intravenously on Day 1 of each treatment cycle
Study: NCT05977322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FF58
Description: Kit for radiopharmaceutical preparation of 68Ga- FF58 solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-FF58
Description: Solution for injection/infusion
Study: NCT05777889

Intervention type: OTHER
Intervention: Forward Looking InfraRed Camera
Description: Forward Looking InfraRed Camera:~1. We will use a FLIR T420 or T62101 camera with a resolution of 320\*240.~2. Each image will be captured perpendicularly with a 1-inch gap on all four sides.~3. A Myler blanket placed in the background will separate the feet from the background.~4. The camera will be normalized to a temperature range of 15°C to 40°C.~5. The images will be saved in radiometric JPEG format.~6. Once the images have been transferred to a computer, we will remove the background.~7. Next, we'll make a temperature histogram with 0.1°C temperature bin resolution.~8. The before and after histograms (IB, IA) will be compared to see which one indicates more extreme temperature distributions.~9. Those who improve by 30% or more are considered to have had a successful spinal cord stimulation.
Study: NCT06407830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor relearning programme
Description: Treatment protocol includes Brief period of warm up and cool down (5 minutes). Individuals of this group will be provided 3 sessions per week; 1 hour per session; 24 sessions of task specific training based on the motor relearning programme. Each task specific training consists of 10 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: motor relearning programme
Description: Treatment protocol includes Brief period of warm up and cool down (5 minutes). Individuals of this group will be provided 3 sessions per week; 1 hour per session; 24 sessions of task specific training based on the motor relearning programme. Each task specific training consists of 10 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrical muscle stimulations with motor relearning programme
Description: Treatment protocol includes Brief period of warm up and cool down (5 minutes). Individuals of this group will be provided 3 sessions per week; 1 hour per session; 24 sessions of task specific training based on the motor relearning programme. Each task specific training consists of 10 minutes.~Individuals of this group will be provided 3 sessions per week; 1 hour per session; 24 sessions for 8 weeks task specific training based on the motor relearning programme and 10 minutes of the EMS of each muscle during the session.
Study: NCT06383676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional reaction balance training
Description: The interventions will carried out two days a week and 40 minutes, for eight weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional balance training
Description: The interventions will carried out two days a week and 40 minutes, for eight weeks.
Study: NCT06251310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SW-682
Description: SW-682 tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SW-682
Description: SW-682 tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SW-682
Description: SW-682 tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SW-682
Description: SW-682 tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SW-682
Description: SW-682 tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Therapy
Description: Appropriate combination therapy
Study: NCT05424237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App intervention
Description: usual care plus app ussage with the aim of promote healthy behaviors (diet, physical activity and weight)
Study: NCT05368883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise- One-Legged
Description: The exercise program consisted of a 5-minute warm-up, followed by 10 minutes of cycling for each leg during the first 2 weeks, increasing to 15 minutes for each leg in the subsequent weeks (with a 5-10 minute rest period between switching legs), and concluded with a 5-minute cool-down period. During the exercise, the inactive leg was kept stationary and in contact with the ground . In the one-legged cycling exercise training, whether patients started with the dominant or non-dominant leg was determined randomly

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise-Two-Legged
Description: The exercise program consisted of a 5-minute warm-up, followed by 20 minutes of cycling during the first 2 weeks, increasing to 30 minutes in the subsequent weeks, and concluded with a 5-minute cool-down period.
Study: NCT04999488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BPM31510
Description: A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.
Study: NCT06291987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Ivosidenib will be given at assigned dose once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Ivosidenib will be given at assigned dose once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Ivosidenib will be given at assigned dose once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be given at assigned dose twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be given at assigned dose twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be given at assigned dose twice daily.
Study: NCT06408207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CGM Academy
Description: Educational materials as well as online sessions with diabetes educators.
Study: NCT06645314

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group A
Description: 3.0 × 10 \^ 9 BST06 cells, intravenous infusion，at least 2 subjects enrolled, up to a maximum of 8 subjects enrolled

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B
Description: 3.0 × 10 \^ 10 BST06 cells, intravenous infusion, at least 2 subjects enrolled, up to a maximum of 8 subjects enrolled
Study: NCT06492460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug：Cisplatin
Description: Concurrent Cisplatin chemotherapy (100 mg/m2 intravenous injection,once every 3 weeks, twice in total, on days 1 and 22) will be given plus intensity modulated radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug：Cisplatin
Description: Concurrent Cisplatin chemotherapy (100 mg/m2 intravenous injection,once every 3 weeks, twice in total, on days 1 and 22) will be given plus intensity modulated radiotherapy
Study: NCT05308446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study: NCT04798885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GAIN 2.0
Description: 1) three structured group sessions of two hours duration performed jointly by a neuropsychologist, an occupational therapist and a physiotherapist. Relatives are also invited. 2) Up to five weekly semi-structured individual sessions of 30 min. duration with an allocated therapist
Study: NCT05308446

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Encorafenib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04999488

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.
Study: NCT04901676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leronlimab
Description: Leronlimab 700 mg (first dose) followed by weekly 350 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06533722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Vinorelbine, or Eribulin
Description: Gemcitabine Gemcitabine 1000 mg/m\^2 IV on days 1 and 8, cycled every 33 days Vinorelbine 25 mg/m\^2 IV on days 1 and 8, cycled every 33 days Eribulin 1.4 mg/m\^2 IV on days 1 and 8, cycled every 33 days